RT Journal Article
T1 Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management.
A1 Bellmunt, Joaquim
A1 Valderrama, Begoña P
A1 Puente, Javier
A1 Grande, Enrique
A1 Bolós, M Victoria
A1 Lainez, Nuria
A1 Vázquez, Sergio
A1 Maroto, Pablo
A1 Climent, Miguel Ángel
A1 Garcia Del Muro, Xavier
A1 Arranz, José Ángel
A1 Durán, Ignacio
K1 Antibody drug-conjugate (ADC)
K1 Avelumab
K1 Bladder cancer
K1 Checkpoint inhibitors (CPIs)
K1 Platinum-based chemotherapy
K1 Switch maintenance
K1 Urothelial carcinoma (UC)
AB Management of first-line advanced urothelial carcinoma (UC) has consisted during the past three decades in the administration of platinum-based chemotherapy followed by observation. Despite moderate to high response rates to first-line treatment, most patients will relapse shortly after and the outcomes with subsequent therapies are poor with 5-year overall survival rates of 5% in the pre-immunotherapy era. Nonetheless, recent therapeutic developments including the paradigm shift of first-line maintenance therapy with avelumab after response or stabilization on platinum-based chemotherapy, along with the incorporation of new drug classes in further lines of treatment such as antibody drug-conjugates and fibroblast growth factor receptor inhibitors have reshaped the field leading to better outcomes in this patient population. This article reviews the current state of the art with an overview on UC management, recent advances, and the upcoming strategies currently in development in advanced UC with an insight into the biology of this disease.
YR 2022
FD 2022-04-16
LK http://hdl.handle.net/10668/22144
UL http://hdl.handle.net/10668/22144
LA en
DS RISalud
RD Apr 19, 2025